BTK
Gli inibitori della tirosina chinasi di Bruton (BTK) sono composti che mirano specificamente a inibire la BTK, un enzima cruciale coinvolto nella segnalazione del recettore delle cellule B e nella regolazione dell'angiogenesi. La BTK svolge un ruolo significativo nella proliferazione e nella sopravvivenza delle cellule cancerose, in particolare nelle malignità ematologiche. Inibendo la BTK, questi composti possono interrompere l'angiogenesi e la crescita tumorale, rendendoli preziosi nella terapia del cancro. Presso CymitQuimica, offriamo una gamma di inibitori della BTK di alta qualità per supportare la tua ricerca in oncologia, immunologia e angiogenesi.
Trovati 157 prodotti di "BTK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Orelabrutinib
CAS:<p>Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).</p>Formula:C26H25N3O3Purezza:97.77% - 99.54%Colore e forma:SolidPeso molecolare:427.49ARQ 531
CAS:<p>ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.</p>Formula:C25H23ClN4O4Purezza:98.68% - 99.63%Colore e forma:SolidPeso molecolare:478.93Rilzabrutinib
CAS:<p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>Formula:C36H40FN9O3Purezza:98.28% - 99.76%Colore e forma:SolidPeso molecolare:665.76IBT6A
CAS:<p>IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Formula:C22H22N6OPurezza:99.8% - 99.88%Colore e forma:SolidPeso molecolare:386.45AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formula:C33H31FN6O3Purezza:≥95%Colore e forma:SolidPeso molecolare:578.64MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formula:C41H41N9O8Purezza:95.93% - 97%Colore e forma:SolidPeso molecolare:787.82Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formula:C24H25N5O3Purezza:99.94%Colore e forma:SolidPeso molecolare:431.49Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formula:C25H23ClN6O3Purezza:99.27% - 99.95%Colore e forma:SolidPeso molecolare:490.94FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Colore e forma:LiquidBTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Formula:C23H32N4O5Colore e forma:SolidPeso molecolare:444.532BTK inhibitor 17
CAS:BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.Formula:C25H24N6O3Purezza:99.57% - 99.88%Colore e forma:SolidPeso molecolare:456.5FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Colore e forma:Odour SolidPCI-33380
CAS:PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.Formula:C46H52BF2N11O3Purezza:98%Colore e forma:SolidPeso molecolare:855.8BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Colore e forma:Odour SolidI-As-1
I-As-1 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 2.35 nM. It exhibits antiproliferative activity against Ramos cells and OCI-LY10 cells, with IC50 values of 0.52 μM and 0.11 μM, respectively.Formula:C26H27AsN6O2S2Peso molecolare:594.08529PROTAC BTK Degrader-12
CAS:<p>PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.</p>Formula:C47H54N12O4Colore e forma:SolidPeso molecolare:851.01PROTAC BTK Degrader-10
CAS:<p>PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].</p>Formula:C42H49N11O4Colore e forma:SolidPeso molecolare:771.91PROTAC BTK Degrader-11
CAS:PROTAC BTK Degrader-11 is a PROTAC degrader that targets and degrades BTK with a DC50 of 1.7 nM. It is utilized in oncological research.Formula:C48H55N11O4Colore e forma:SolidPeso molecolare:850.02PROTAC BTK Degrader-5
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity byFormula:C52H57ClFN9O6Purezza:98%Colore e forma:SolidPeso molecolare:958.52PROTAC BTK Degrader-13
<p>PROTAC BTK Degrader-13 (Compound 25) is a targeted BTK PROTAC degrader with a DC50 of 0.27 μM. It inhibits BTK activity with an IC50 of 0.44 μM and suppresses IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. This compound also inhibits the p38 MAPK signaling pathway, thereby blocking the activation of the BCR (B cell receptor) signaling pathway. [Pink: ligand for target protein BTK ligand 15; Black: linker; Blue: ligand for E3 ligase cereblon]</p>Formula:C33H30N6O7Colore e forma:SolidPeso molecolare:622.63GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purezza:98%Colore e forma:SolidPeso molecolare:797.9QL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Formula:C25H20ClN5O2Purezza:99.25%Colore e forma:SoildPeso molecolare:457.91BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Colore e forma:SolidPeso molecolare:527.508PROTAC BTK Degrader-8
PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.Formula:C80H94F2N14O20P2Peso molecolare:1670.62121PROTAC BTK Degrader-9
<p>PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.</p>Formula:C46H52FN13O5Peso molecolare:885.41984BIIB091
CAS:BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Formula:C28H34N10O2Colore e forma:SolidPeso molecolare:542.648CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurezza:98%Colore e forma:SolidPeso molecolare:961.18BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formula:C58H65F2N11O8Colore e forma:SolidPeso molecolare:1082.224PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formula:C47H54F2N8O13Colore e forma:SolidPeso molecolare:976.97NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Colore e forma:SolidPeso molecolare:817.94BRK inhibitor P21d hydrochloride
CAS:<p>BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.</p>Formula:C23H23ClFN7O2Colore e forma:SolidPeso molecolare:483.93PROTAC BTK Degrader-6
CAS:<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Formula:C45H47N11O6Purezza:98%Colore e forma:SolidPeso molecolare:837.92PTD10
CAS:PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.Formula:C49H51N11O8Purezza:99.12%Colore e forma:SolidPeso molecolare:922SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purezza:98%Colore e forma:SolidPeso molecolare:797.3Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formula:C50H48N12O4Purezza:98%Colore e forma:SolidPeso molecolare:880.99PROTAC BTK Degrader-1
CAS:<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Formula:C43H43N9O4Colore e forma:SolidPeso molecolare:749.86DBt-10
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].Formula:C68H86ClFN16O6Purezza:98%Colore e forma:SolidPeso molecolare:1277.96DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Formula:C55H62N10O8Colore e forma:SolidPeso molecolare:991.163Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Formula:C56H80N12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1097.39TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Colore e forma:Odour SolidBTK-IN-40
CAS:BTK-IN-40 (compound 375) is an inhibitor of BTK.Formula:C20H25N7O2Colore e forma:SolidPeso molecolare:395.46Tyrosinase-IN-16
CAS:<p>Tyrosinase-IN-16 inhibited tyrosinase.</p>Formula:C8H6BrN3SPurezza:99.57%Colore e forma:SolidPeso molecolare:256.12Acalabrutinib enantiomer
CAS:<p>R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.</p>Formula:C26H23N7O2Purezza:97.27%Colore e forma:SolidPeso molecolare:465.51evobrutinib
CAS:<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Formula:C25H27N5O2Purezza:98.03% - 99.58%Colore e forma:SolidPeso molecolare:429.51N-piperidine Ibrutinib hydrochloride
CAS:N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.Formula:C22H23ClN6OPurezza:98.83%Colore e forma:SolidPeso molecolare:422.91IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Formula:C22H23ClN6OColore e forma:SolidPeso molecolare:422.91Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Colore e forma:Odour LiquidNX-5948
CAS:<p>NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.</p>Formula:C42H54N12O5Purezza:98.29%Colore e forma:SolidPeso molecolare:806.96Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Formula:C17H19N3O2Purezza:99.77%Colore e forma:SolidPeso molecolare:297.36Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Formula:C26H26N6O3Purezza:99.98%Colore e forma:SolidPeso molecolare:470.52GDC-0834
CAS:GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse andFormula:C33H36N6O3SColore e forma:SolidPeso molecolare:596.74(Rac)-IBT6A
CAS:(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurezza:99.24%Colore e forma:SolidPeso molecolare:386.45CGI-1746
CAS:CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.Formula:C34H37N5O4Purezza:97.69% - 97.88%Colore e forma:SolidPeso molecolare:579.69TL-895
CAS:<p>TL-895 is a potent, selective ATP-competitive BTK inhibitor (IC50 = 1.5 nM, Ki = 11.9 nM).</p>Formula:C25H26FN5O2Purezza:99.96%Colore e forma:SolidPeso molecolare:447.5Olmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Formula:C26H26N6O2SPurezza:99.14% - 99.63%Colore e forma:SolidPeso molecolare:486.59CNX-774
CAS:CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).Formula:C26H22FN7O3Purezza:97.35% - 99.11%Colore e forma:SolidPeso molecolare:499.5ONO-4059 analog
CAS:ONO-4059 analog (ONO-WG-307)ue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.Formula:C25H24N6O3Purezza:99.25%Colore e forma:SolidPeso molecolare:456.5Ibrutinib
CAS:Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.Formula:C25H24N6O2Purezza:98% - 99.93%Colore e forma:SolidPeso molecolare:440.5BTK IN-1
CAS:<p>BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).</p>Formula:C19H21ClN6OPurezza:97.38%Colore e forma:SolidPeso molecolare:384.86Tolebrutinib
CAS:<p>Tolebrutinib is an oral, selective BTK inhibitor, effective for MS research, with brain penetration and IC50s of 0.4/0.7 nM in cells.</p>Formula:C26H25N5O3Purezza:98.4% - 98.82%Colore e forma:SolidPeso molecolare:455.51Branebrutinib
CAS:<p>Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family.</p>Formula:C20H23FN4O2Purezza:95.86% - 99.31%Colore e forma:SolidPeso molecolare:370.42Acalabrutinib
CAS:Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.Formula:C26H23N7O2Purezza:98.94% - 99.64%Colore e forma:SolidPeso molecolare:465.51Fenebrutinib
CAS:<p>Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).</p>Formula:C37H44N8O4Purezza:98.26% - 98.94%Colore e forma:SolidPeso molecolare:664.8BMS-986142
CAS:BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).Formula:C32H30F2N4O4Purezza:99.44% - 99.76%Colore e forma:SolidPeso molecolare:572.6Remibrutinib
CAS:<p>Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood.</p>Formula:C27H27F2N5O3Purezza:99.5% - 99.81%Colore e forma:SolidPeso molecolare:507.53PCI 29732
CAS:<p>PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.</p>Formula:C22H21N5OPurezza:99.81%Colore e forma:SolidPeso molecolare:371.43(S)-Sunvozertinib
CAS:(S)-Sunvozertinib (DZD9008) is a rationally designed selective, irreversible EGFR/HER2 inhibitor.Formula:C29H35ClFN7O3Purezza:99.64%Colore e forma:SolidPeso molecolare:584.08Avitinib
CAS:Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor,Formula:C26H26FN7O2Purezza:99.81% - >99.99%Colore e forma:SolidPeso molecolare:487.53BIIB068
CAS:BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.Formula:C23H29N7O2Purezza:97.98%Colore e forma:SolidPeso molecolare:435.52Larotinib mesylate hydrate
CAS:Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nMFormula:C26H36ClFN4O11S2Colore e forma:SolidPeso molecolare:699.17RN486
CAS:<p>RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).</p>Formula:C35H35FN6O3Purezza:99.38%Colore e forma:SolidPeso molecolare:606.69zanubrutinib
CAS:Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).Formula:C27H29N5O3Purezza:98.42% - 99.76%Colore e forma:SolidPeso molecolare:471.55Spebrutinib
CAS:Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplasticFormula:C22H22FN5O3Purezza:97.02% - >99.99%Colore e forma:SolidPeso molecolare:423.44CHMFL-BMX-078
CAS:CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.Formula:C33H35N7O6Purezza:>99.99%Colore e forma:SolidPeso molecolare:625.67N-piperidine Ibrutinib
CAS:<p>N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively.</p>Formula:C22H22N6OPurezza:96.65%Colore e forma:SolidPeso molecolare:386.45Ibrutinib deacryloylpiperidine
CAS:Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.Formula:C17H13N5OPurezza:99.47%Colore e forma:SolidPeso molecolare:303.32(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Formula:C11H8Br2N2O2Purezza:99.88%Colore e forma:SolidPeso molecolare:360BTK Protein, Human, Recombinant (His)
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling.Purezza:90%Colore e forma:Lyophilized PowderPeso molecolare:78.3 kDa (predicted)Ibrutinib-d5
CAS:Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.Formula:C25H24N6O2Purezza:98%Colore e forma:SolidPeso molecolare:445.53CP-547632
CAS:CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.Formula:C20H24BrF2N5O3SPurezza:99.14%Colore e forma:SolidPeso molecolare:532.4DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formula:C25H26ClN7O3Colore e forma:SolidPeso molecolare:507.97CHMFL-BTK-01
CAS:<p>CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.</p>Formula:C38H41N5O5Purezza:98%Colore e forma:SolidPeso molecolare:647.76Spebrutinib besylate
CAS:<p>Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).</p>Formula:C28H28FN5O6SPurezza:98%Colore e forma:SolidPeso molecolare:581.62BLK-IN-2
CAS:<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Formula:C39H41N9O3Colore e forma:SolidPeso molecolare:683.8BLK degrader 1
CAS:<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Formula:C32H25F3N6O2Purezza:99.22% - 99.24%Colore e forma:SolidPeso molecolare:582.58ACP-5862
CAS:ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.Formula:C26H23N7O3Colore e forma:SolidPeso molecolare:481.51JAK3/BTK-IN-5
CAS:JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.Formula:C19H22ClN7O2Colore e forma:SolidPeso molecolare:415.88JAK3/BTK-IN-6
CAS:JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.Formula:C21H17BF3N5O3Colore e forma:SolidPeso molecolare:455.2(R)-Elsubrutinib
CAS:(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.Formula:C17H19N3O2Purezza:99.05%Colore e forma:SolidPeso molecolare:297.35JS25
CAS:JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.Formula:C29H24N4O4SColore e forma:SolidPeso molecolare:524.59BLK-IN-1
CAS:BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.Formula:C29H23F3N6O3Colore e forma:SolidPeso molecolare:560.53BTK inhibitor 10
CAS:BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Formula:C25H23N5O3Purezza:98%Colore e forma:SolidPeso molecolare:441.48Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Formula:C32H39N9O2Colore e forma:SolidPeso molecolare:581.71SB-633825
CAS:SB-633825 can inhibit cancer cell growth and angiogenesis.Formula:C28H25N3O3SPurezza:98%Colore e forma:SolidPeso molecolare:483.58HZ-A-005
CAS:HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.Formula:C25H23ClN6O2Colore e forma:SolidPeso molecolare:474.94GDC-0834 S-enantiomer
CAS:GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).Formula:C33H36N6O3SPurezza:98%Colore e forma:SolidPeso molecolare:596.74CGI560
CAS:CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.Formula:C29H27N5OColore e forma:SolidPeso molecolare:461.56VA5 TG2 inhibitor
CAS:VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.Formula:C31H34N4O8Purezza:98%Colore e forma:SolidPeso molecolare:590.62JNJ-64264681
CAS:JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).Formula:C27H30N6O3SPurezza:98%Colore e forma:SolidPeso molecolare:518.63BTK-IN-22
CAS:BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.Formula:C26H26N6O2Colore e forma:SolidPeso molecolare:454.52SJF620
CAS:SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).Formula:C41H44N8O7Purezza:98%Colore e forma:SolidPeso molecolare:760.84BTK-IN-23
CAS:BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.Formula:C27H28N6O2Colore e forma:SolidPeso molecolare:468.55EGFR-IN-40
CAS:EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).Formula:C23H20N6O3Colore e forma:SolidPeso molecolare:428.44GDC-0834 Racemate
CAS:GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitorFormula:C33H36N6O3SColore e forma:SolidPeso molecolare:596.74BI-1622
CAS:BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.Formula:C26H24N10O2Colore e forma:SolidPeso molecolare:508.53PF-06465469
CAS:PF-06465469, a covalent ITK and BTK inhibitor (IC₅₀ = 2 nM), suppresses CXCL12-mediated migration and decreases PD-1/LAG-3 for leukemia and lymphoma research.Formula:C30H33N7O2Purezza:98%Colore e forma:SolidPeso molecolare:523.63(R)-Zanubrutinib
CAS:(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).Formula:C27H29N5O3Purezza:99.55%Colore e forma:SolidPeso molecolare:471.55Larotinib
CAS:Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.Formula:C24H26ClFN4O4Purezza:99.73%Colore e forma:SolidPeso molecolare:488.94(±)-Zanubrutinib
CAS:(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,Formula:C27H29N5O3Purezza:99.09%Colore e forma:SolidPeso molecolare:471.55NX-2127
CAS:NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferativeFormula:C39H45N9O5Purezza:99.07%Colore e forma:SolidPeso molecolare:719.83Tilfrinib
CAS:<p>Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.</p>Formula:C17H13N3OPurezza:99.54%Colore e forma:SolidPeso molecolare:275.3Sunvozertinib
CAS:Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.Formula:C29H35ClFN7O3Purezza:98.11% - 99.63%Colore e forma:SolidPeso molecolare:584.08CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Formula:C25H24ClN7O2Purezza:99.66%Colore e forma:SolidPeso molecolare:489.96BTK inhibitor 20
CAS:BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Formula:C37H42N8O4Colore e forma:SolidPeso molecolare:662.78BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Formula:C26H22ClN5O3Colore e forma:SolidPeso molecolare:487.94BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Formula:C26H23N7O2Colore e forma:SolidPeso molecolare:465.51BTK-IN-18
CAS:BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Formula:C20H22Cl2N6OColore e forma:SolidPeso molecolare:433.33(Rac)-PF-06250112
CAS:(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Formula:C22H20F2N6O2Purezza:98%Colore e forma:SolidPeso molecolare:438.43BTK-IN-19
CAS:BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .Formula:C21H22Cl2N6OColore e forma:SolidPeso molecolare:445.35PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Formula:C22H21ClN6O2Colore e forma:SolidPeso molecolare:436.89BTK inhibitor 13
CAS:BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).Formula:C29H26FN5O3Purezza:98%Colore e forma:SolidPeso molecolare:511.55DDa-1
CAS:DDa-1 is a potent (kinase degrader) [1].Formula:C60H77Cl2N13O3SColore e forma:SoildPeso molecolare:1131.31Edralbrutinib
CAS:Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFormula:C26H21F2N5O3Purezza:99.41%Colore e forma:SolidPeso molecolare:489.47Pirtobrutinib
CAS:<p>Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.</p>Formula:C22H21F4N5O3Purezza:99.76% - 99.94%Colore e forma:SolidPeso molecolare:479.43BMX-IN-1
CAS:BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFormula:C29H24N4O4SPurezza:98.38%Colore e forma:SolidPeso molecolare:524.59Cinsebrutinib
CAS:<p>Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.</p>Formula:C22H26FN3O2Purezza:98%Colore e forma:SolidPeso molecolare:383.46PF-06250112
CAS:PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.Formula:C22H20F2N6O2Purezza:98%Colore e forma:SolidPeso molecolare:438.43TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formula:C18H17N5O3Purezza:98.66%Colore e forma:SolidPeso molecolare:351.36BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Formula:C24H23FN8O2Purezza:98.24% - 98.91%Colore e forma:SolidPeso molecolare:474.49BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purezza:99.89%Colore e forma:SolidPeso molecolare:502.56TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Formula:C40H47N11O5Colore e forma:SolidPeso molecolare:761.87(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Formula:C25H22N6O2Colore e forma:SolidPeso molecolare:438.48BTK-IN-10
CAS:BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formula:C25H24F2N4O2Colore e forma:SolidPeso molecolare:450.48BTK-IN-16
CAS:BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.Formula:C15H14N4O2Purezza:99.04%Colore e forma:SoildPeso molecolare:282.3BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formula:C22H29N3O4SPeso molecolare:431.55HDHD4-IN-1
CAS:HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formula:C12H22NO11PColore e forma:SolidPeso molecolare:387.28JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formula:C21H25ClN8OColore e forma:SolidPeso molecolare:440.93BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formula:C31H24Cl2N4O4Colore e forma:SolidPeso molecolare:587.45JAK3/BTK-IN-7
CAS:JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].Formula:C29H30N8O4Colore e forma:SolidPeso molecolare:554.6BTK-IN-38
CAS:BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Formula:C27H26F2N4O2Colore e forma:SolidPeso molecolare:476.52BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formula:C35H35ClN4O3SPeso molecolare:627.2G-744
CAS:G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).Formula:C29H29N5O3SPurezza:98%Colore e forma:SolidPeso molecolare:527.64JAK3/BTK-IN-3
CAS:JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formula:C22H28N8OColore e forma:SolidPeso molecolare:420.51BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formula:C29H25N5O4S2Colore e forma:SolidPeso molecolare:571.67BIIB129
CAS:<p>BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.</p>Formula:C19H22N6O2Purezza:98.56%Colore e forma:SolidPeso molecolare:366.42BTK-IN-8
<p>BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).</p>Formula:C26H36N6O3Colore e forma:SolidPeso molecolare:480.6WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formula:C26H22FN9O2Colore e forma:SolidPeso molecolare:511.51Brefeldin A 4-O-nicotinate
CAS:Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.Formula:C22H27NO5Colore e forma:SolidPeso molecolare:385.453BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Formula:C23H22FN5O3Colore e forma:SolidPeso molecolare:435.45BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formula:C28H24FN5O2Colore e forma:SolidPeso molecolare:481.52GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formula:C30H32N10O2Colore e forma:SolidPeso molecolare:564.64RET-IN-14
CAS:RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Formula:C24H23FN8O4Colore e forma:SolidPeso molecolare:506.49Ibrutinib Racemate
CAS:Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formula:C25H24N6O2Purezza:98%Colore e forma:SolidPeso molecolare:440.5Dihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formula:C25H26N6O4Colore e forma:SolidPeso molecolare:474.521BTK-IN-25
CAS:<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Formula:C28H27F2N3O5Purezza:98%Colore e forma:SolidPeso molecolare:523.53BTK-IN-27
CAS:<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Formula:C31H35N7O2Purezza:98%Colore e forma:SolidPeso molecolare:537.66JDB175
CAS:<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Formula:C26H21F3N4O2Purezza:98%Colore e forma:SolidPeso molecolare:478.47
